Lupin Enters Canadian Biosimilars Market With Etanercept
Rymti Rival To Amgen’s Enbrel Is Launched With Partner Sandoz
Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.
